A single dose, 4-period, cross-over, bioequivalence and drug-drug interaction study in healthy subjects to evaluate the fixed combination tablet of candesartan cilexetil/hydrochlorothiazide 32/25 mg
Study identifier:D2456C00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A single dose, 4-period, cross-over, bioequivalence and drug-drug interaction study in healthy subjects to evaluate the fixed combination tablet of candesartan cilexetil/hydrochlorothiazide 32/25 mg
Medical condition
hypertension
Phase
Phase 1
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jun 2007
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
